Announcements
- Annovis Announces New Publication in a Peer-Reviewed Journal
- Annovis Bio Provides Corporate Updates and Announces First Quarter 2024 Financial Results
- Annovis Announces Unblinding of the Buntanetap Phase III Data in Parkinson’s Disease
- Annovis Bio CEO Maria Maccecchini Issues Letter to Stockholders
- Annovis Bio Announces Statistically Significant Phase II/III Data in Patients With Early Alzheimer’s Disease
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
- Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
- Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
More ▼
Key statistics
On Monday, Annovis Bio Inc (07X:DEU) closed at 6.23, 40.95% above the 52 week low of 4.42 set on May 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.97 |
---|---|
High | 6.35 |
Low | 5.97 |
Bid | 6.18 |
Offer | 6.38 |
Previous close | 6.05 |
Average volume | 2.26k |
---|---|
Shares outstanding | 11.17m |
Free float | 8.36m |
P/E (TTM) | -- |
Market cap | 73.17m USD |
EPS (TTM) | -5.04 USD |
Data delayed at least 15 minutes, as of Jun 03 2024.
More ▼